Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA Transaction Represents Kamada’s Entry into U.S. Plasma Collection Market and Advances the Company’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Blood and Plasma Research, Inc. Primarily Focuses on Collecting Hyper-Immune Plasma, and Kamada Plans to Significantly […]
The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024 Potential Collective Maximum Sales of the Three Products in the Israeli Market is Estimated at $5-$7 Million Annually These Sales Are in Addition to the Potential $20-$30 Million from the Recently Licensed Alvotech Biosimilar Portfolio REHOVOT, […]
Rehovot, Israel, January 5, 2021 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it has been selected as one of 10 winners of the Genesis Prize Foundation (GPF) Start-Up Nation Central (SNC) competition recognizing Israeli companies working to combat coronavirus and the damage of future pandemics. Based on its development […]
REHOVOT, Israel – December 21, 2020 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology […]
Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue Guidance of $132 Million to $137 Million. Net Income for Third Quarter and First Nine Months of 2020 was $6.8 million and $15.5 million, Respectively, […]
Treatment with Kamada’s Investigational IgG Product Will Be Regulated by the Israeli Ministry of Health. Initial Order Sufficient to Treat 500 Patients. Positive Interim Safety and Symptoms Improvement Observed in Fully Enrolled Ongoing Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial of Company’s Hyperimmune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia. S. Clinical […]
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement Kamada Projects Royalties from Takeda in the Range of $10 Million to $20 Million per Year from 2022 to 2040 Kamada Reiterates its Total Revenues Guidance […]
The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyper-immune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia Symptoms Improvement Observed in 11 of the 12 Patients within 24 to 48 Hours of Treatment; All 11 Patients Subsequently Discharged from Hospital within a Median of 4.5 Days from Treatment. IgG Product […]
The Study of KEDRAB® (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S. The Study Met its Primary Objective, Which Was to Confirm the Safety of KEDRAB in the Pediatric Population. Study Results Have Been Submitted to the U.S. FDA for Review and Potential […]
Click here for the recording of Kamada second quarter 2020 investor call. Second Quarter Revenues were $1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019. Net Income for the Second Quarter and for the First Half of 2020 was $3.5 million and $8.7 million, Respectively, Compared […]